What is MOSS?
MOSS Inc. operates as a critical infrastructure provider for the life sciences industry, specializing in the production of high-quality, liquid-stable immunoassay reagents. With a legacy spanning over 34 years, the company has established itself as a reliable partner for pharmaceutical, biotechnology, and veterinary diagnostic firms. Their core competency lies in bulk manufacturing and custom service delivery, underpinned by ISO-9001-2015 certification. By prioritizing lot-to-lot consistency and product stability—often exceeding 36 months—MOSS serves as a foundational supplier for assay development and large-scale production, ensuring that diagnostic manufacturers maintain the sensitivity required for high-stakes medical and research applications.
How much funding has MOSS raised?
MOSS has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in MOSS
PPP
Public-Private Partnership
What's next for MOSS?
With this late-stage capital, MOSS is well-positioned to scale its manufacturing capabilities and further penetrate international markets. The strategic focus will likely shift toward optimizing supply chain efficiencies and expanding its custom service portfolio to meet the evolving demands of the diagnostics industry. As the company leverages its deep technical expertise, it remains poised to capitalize on the increasing global demand for stable, high-performance immunoassay components, ensuring its continued relevance as a key supplier to leading manufacturers and distributors worldwide.
See full MOSS company page
